MA51151A - Inhibiteurs d'endo-exonucléase mono- et di-amidine et procédés d'inhibition de l'activité endo-exonucléase - Google Patents

Inhibiteurs d'endo-exonucléase mono- et di-amidine et procédés d'inhibition de l'activité endo-exonucléase

Info

Publication number
MA51151A
MA51151A MA051151A MA51151A MA51151A MA 51151 A MA51151 A MA 51151A MA 051151 A MA051151 A MA 051151A MA 51151 A MA51151 A MA 51151A MA 51151 A MA51151 A MA 51151A
Authority
MA
Morocco
Prior art keywords
endo
exonuclease
amidine
mono
methods
Prior art date
Application number
MA051151A
Other languages
English (en)
Inventor
Terry Chow
Original Assignee
Montdorex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Montdorex Inc filed Critical Montdorex Inc
Publication of MA51151A publication Critical patent/MA51151A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/18—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to carbon atoms of six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
MA051151A 2017-11-16 2018-11-08 Inhibiteurs d'endo-exonucléase mono- et di-amidine et procédés d'inhibition de l'activité endo-exonucléase MA51151A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762587118P 2017-11-16 2017-11-16

Publications (1)

Publication Number Publication Date
MA51151A true MA51151A (fr) 2020-10-21

Family

ID=66538346

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051151A MA51151A (fr) 2017-11-16 2018-11-08 Inhibiteurs d'endo-exonucléase mono- et di-amidine et procédés d'inhibition de l'activité endo-exonucléase

Country Status (9)

Country Link
US (2) US11103468B2 (fr)
EP (1) EP3724161B1 (fr)
JP (2) JP7153734B2 (fr)
CN (1) CN111448181B (fr)
AU (1) AU2018367939B2 (fr)
CA (2) CA3075664C (fr)
IL (1) IL274340B2 (fr)
MA (1) MA51151A (fr)
WO (1) WO2019095046A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024197407A1 (fr) * 2023-03-28 2024-10-03 Montdorex Inc. Analogues de diamidine à usage anti-inflammatoire

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU164584B (fr) 1971-11-19 1974-03-28
JPS60130561A (ja) * 1983-12-16 1985-07-12 Torii Yakuhin Kk アミジン誘導体およびそれを含む強心剤
US5324830A (en) 1991-03-26 1994-06-28 United States Of America Chimeric protein that has a human RHo Motif and deoxyribonuclease activity
US5489524A (en) 1991-03-26 1996-02-06 The United States Of America As Represented By The Department Of Health And Human Services Chimeric protein that has a human Rho motif and deoxyribonuclease activity
DK1231910T3 (da) * 1999-11-16 2009-08-31 Oncozyme Pharma Inc Pentamidin til behandling af cancer
US7115665B1 (en) 2000-11-16 2006-10-03 Onocozyme Pharma, Inc. Inhibitors of endo-exonuclease activity for treating cancer
WO2005079780A1 (fr) * 2004-01-23 2005-09-01 Neurochem (International) Limited Derives d'amidine pour le traitement de l'amylose
US7585881B2 (en) * 2004-02-18 2009-09-08 Astrazeneca Ab Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
CN101481332B (zh) * 2009-02-26 2012-08-29 南京华狮化工有限公司 一种烷氧基芳脒化合物的合成方法
MX2015007945A (es) * 2012-12-21 2016-02-16 Verlyx Pharma Inc Usos y métodos para el tratamiento de enfermedades o afecciones hepáticas.
TWI632127B (zh) * 2015-06-03 2018-08-11 日本曹達股份有限公司 胍化合物及殺菌劑
CN106946790B (zh) 2017-04-26 2019-08-06 华侨大学 一种1,2-取代苯并咪唑类衍生物的制备方法

Also Published As

Publication number Publication date
CA3075664A1 (fr) 2019-05-23
EP3724161A1 (fr) 2020-10-21
CA3086099C (fr) 2023-05-09
IL274340A (en) 2020-06-30
JP7395642B2 (ja) 2023-12-11
US20210338607A1 (en) 2021-11-04
WO2019095046A1 (fr) 2019-05-23
JP7153734B2 (ja) 2022-10-14
EP3724161A4 (fr) 2021-09-08
IL274340B1 (en) 2023-01-01
US11103468B2 (en) 2021-08-31
CN111448181A (zh) 2020-07-24
US20200375924A1 (en) 2020-12-03
IL274340B2 (en) 2023-05-01
CN111448181B (zh) 2023-05-19
EP3724161C0 (fr) 2025-01-01
CA3075664C (fr) 2020-12-29
JP2022105018A (ja) 2022-07-12
US12239617B2 (en) 2025-03-04
AU2018367939A1 (en) 2020-06-18
EP3724161B1 (fr) 2025-01-01
JP2021503016A (ja) 2021-02-04
CA3086099A1 (fr) 2019-05-23
AU2018367939B2 (en) 2023-07-13

Similar Documents

Publication Publication Date Title
EP3368541A4 (fr) Compositions et procédés d'inhibition de l'activité de l'arginase
MA42269A (fr) Compositions et procédés d'inhibition de l'activité de l'arginase
IL267532B (en) Preparations and methods for inhibiting arginase activity
EP3600318A4 (fr) Procédés d'utilisation d'inhibiteurs d'ehmt2
MA51066A (fr) Inhibiteurs d'intégrine
MA51616A (fr) Inhibiteurs d'adn-pk
MA44990A (fr) Polythérapies d'inhibiteurs de hdac et d'inhibiteurs de pd-l1
EP3906029A4 (fr) Inhibiteurs de l'interaction ménine-mll
EP3380101A4 (fr) Composés inhibiteurs d'eif4-a et procédés associés
EP3497086A4 (fr) Inhibiteurs d'amino pyrimidine ssao
MA44991A (fr) Polythérapies d'inhibiteurs de hdac et d'inhibiteurs de pd-1
EP3349743A4 (fr) Procédés et compositions d'inhibition de l'interaction dcn1-ubc12
EP3474879A4 (fr) Compositions et procédés de traitement d'un mélanome
EP3707260A4 (fr) Composés et procédés permettant de réduire l'expression de snca
EP3688132A4 (fr) Solutions de décapage et procédés d'utilisation de solutions de décapage
MA52004A (fr) Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase
IL280051A (en) EP4 inhibitors and their synthesis
MA49006A (fr) Inhibiteurs d'ip6k
EP3810109A4 (fr) Compositions et procédés d'inhibition de cd73
EP3458448A4 (fr) Procédés d'utilisation d'inhibiteurs de fasn
EP3443141A4 (fr) Composition et procédé d'inhibition de la corrosion
EP3478315A4 (fr) Méthodes et compositions d'inhibition du récepteur immunitaire inhibiteur
MA50906A (fr) Inhibiteurs d'immunoprotéasome
MA53648A (fr) Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glucopyranosidase
EP3261631C0 (fr) Inhibition de l'activité d'olig2